Brokerages Expect Praxis Precision Medicines, Inc. (NASDAQ:PRAX) to Post -$1.29 EPS

Wall Street brokerages expect Praxis Precision Medicines, Inc. (NASDAQ:PRAXGet Rating) to report ($1.29) earnings per share (EPS) for the current quarter, Zacks reports. Zero analysts have made estimates for Praxis Precision Medicines’ earnings. The lowest EPS estimate is ($1.41) and the highest is ($1.18). Praxis Precision Medicines reported earnings of ($0.71) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 81.7%. The firm is scheduled to announce its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that Praxis Precision Medicines will report full year earnings of ($5.25) per share for the current year, with EPS estimates ranging from ($6.07) to ($4.75). For the next year, analysts anticipate that the firm will report earnings of ($5.29) per share, with EPS estimates ranging from ($6.31) to ($4.56). Zacks Investment Research’s EPS averages are an average based on a survey of analysts that cover Praxis Precision Medicines.

Praxis Precision Medicines (NASDAQ:PRAXGet Rating) last posted its earnings results on Monday, February 28th. The company reported ($1.30) EPS for the quarter, missing analysts’ consensus estimates of ($1.08) by ($0.22).

PRAX stock opened at $8.64 on Friday. Praxis Precision Medicines has a 1-year low of $8.37 and a 1-year high of $32.60. The firm has a fifty day moving average price of $11.85 and a two-hundred day moving average price of $16.18. The firm has a market cap of $393.03 million, a price-to-earnings ratio of -2.22 and a beta of 2.29.

Hedge funds have recently added to or reduced their stakes in the business. Point72 Hong Kong Ltd bought a new stake in Praxis Precision Medicines during the fourth quarter valued at $31,000. Royal Bank of Canada grew its position in shares of Praxis Precision Medicines by 93.6% during the second quarter. Royal Bank of Canada now owns 1,673 shares of the company’s stock worth $31,000 after acquiring an additional 809 shares during the last quarter. Nisa Investment Advisors LLC bought a new position in shares of Praxis Precision Medicines during the fourth quarter worth about $56,000. Ensign Peak Advisors Inc bought a new position in shares of Praxis Precision Medicines during the fourth quarter worth about $86,000. Finally, Cubist Systematic Strategies LLC grew its position in shares of Praxis Precision Medicines by 29.5% during the fourth quarter. Cubist Systematic Strategies LLC now owns 9,599 shares of the company’s stock worth $189,000 after acquiring an additional 2,189 shares during the last quarter. Hedge funds and other institutional investors own 96.52% of the company’s stock.

Praxis Precision Medicines Company Profile (Get Rating)

Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor.

See Also

Get a free copy of the Zacks research report on Praxis Precision Medicines (PRAX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Praxis Precision Medicines (NASDAQ:PRAX)

Receive News & Ratings for Praxis Precision Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Praxis Precision Medicines and related companies with MarketBeat.com's FREE daily email newsletter.